Click on one of these terms to refine your search
1 to 10 of 17 literature results
-
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Lenalidomide and pomalidomide have both been evaluated clinically for their properties as anticancer agents, with lenalidomide being available commerc…
Authors: Laure Escoubet-Lozach, I-Lin Lin, Kristen Jensen-Pergakes, Helen A Brady, Anita K Gandhi, Peter H Schafer, George W Muller, Peter J Worland, Kyle W H Chan, Dominique Verhelle
Source: Cancer research. 2009 Sep 15
View Full Text -
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Clinical studies involving patients with myelodysplastic syndromes or multiple myeloma have shown the efficacy of lenalidomide by reducing and often e…
Authors: Dominique Verhelle, Laura G Corral, Kevin Wong, Jessica H Mueller, Laure Moutouh-de Parseval, Kristen Jensen-Pergakes, Peter H Schafer, Roger Chen, Emilia Glezer, Gregory D Ferguson,…
Source: Cancer research. 2007 Jan 15
View Full Text -
The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
We have found that the synthetic compound CC-5079 potently inhibits cancer cell growth in vitro and in vivo by a novel combination of molecular mechan…
Authors: Ling-Hua Zhang, Lei Wu, Heather K Raymon, Roger S Chen, Laura Corral, Michael A Shirley, Rama Krishna Narla, Jim Gamez, George W Muller, David I Stirling,…
Source: Cancer research. 2006 Jan 15
View Full Text -
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
In this communication, we report the discovery of 1S (apremilast), a novel potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis fact…
Authors: Hon-Wah Man, Peter Schafer, Lu Min Wong, Rebecca T Patterson, Laura G Corral, Heather Raymon, Kate Blease, Jim Leisten, Michael A Shirley, Yang Tang,…
Source: Journal of medicinal chemistry. 2009 Mar 26
View Full Text -
Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells.
OBJECTIVES: Pancreatic cancer is one of the leading causes of cancer related deaths in the western world. It is also resistant to most chemotherapeuti…
Authors: Petros X E Mouratidis, Kay W Colston, Jake Blake Bartlett, George W Muller, Hon-Wah Man, David Stirling, Angus G Dalgleish
Source: Pancreas. 2009 Jan
View Full Text -
Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition.
Selective cytokine inhibitory drugs (SelCIDs) are a novel class of phosphodiesterase 4 inhibitors discovered during a thalidomide analog discovery pro…
Authors: Michael S Gee, Sosina Makonnen, Khalid al-Kofahi, Badri Roysam, Faribourz Payvandi, Hon-Wah Man, George W Muller, William M F Lee
Source: Cancer research. 2003 Dec 1
View Full Text -
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
Thalidomide is clinically useful in a number of cancers. Antitumor activity may be related to a number of known properties, including anti-tumor necro…
Authors: J Blake Marriott, Ian A Clarke, Anna Czajka, Keith Dredge, Kay Childs, Hon-Wah Man, Peter Schafer, Sowmya Govinda, George W Muller, David I Stirling,…
Source: Cancer research. 2003 Feb 1
View Full Text -
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Lenalidomide (Revlimid) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic…
Authors: Ling Lu, Faribourz Payvandi, Lei Wu, Ling-Hua Zhang, Robert J Hariri, Hon-Wah Man, Roger S Chen, George W Muller, Christopher C W Hughes, David I Stirling,…
Source: Microvascular research. 2009 Mar
View Full Text -
Alpha-fluoro-substituted thalidomide analogues.
Thalidomide, (1), has made a remarkable comeback from its days of a sedative with teratogenic properties due to its ability to selectively inhibit TNF…
Authors: Hon-Wah Man, Laura G Corral, David I Stirling, George W Muller
Source: Bioorganic & medicinal chemistry letters. 2003 Oct 20
View Full Text -
Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner.
Immunomodulatory drugs (IMiDs) are potent inhibitors of TNF-alpha and IL-1beta and elevators of IL-10 production in LPS-stimulated human PBMC. They ar…
Authors: Faribourz Payvandi, Lei Wu, Maura Haley, Peter H Schafer, Ling-Hua Zhang, Roger S Chen, George W Muller, David I Stirling
Source: Cellular immunology. 2004 Aug
View Full Text
